logo
Inhibrx_Logo
Inhibrx utilizes diverse methods of protein engineering in the construction of therapeutic candidates that can address the specific requirements of complex target and disease biology. A key tool for this effort is the Inhibrx proprietary single-domain antibody (sdAb) platform, which enables the development of therapeutic candidates with attributes superior to other monoclonal antibody and fusion protein approaches.

Inhibrx Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights

Inhibrx, Inc. (Nasdaq: INBX), a biopharmaceutical company with four clinical programs in development and a strong emerging pipeline, today reported financial results for the third quarter of 2022 and provided an update on recent corporate highlights

By AP News
Published - Nov 07, 2022, 04:18 PM ET
Last Updated - Mar 21, 2024, 11:28 AM EDT

SAN DIEGO, Nov. 7, 2022 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a biopharmaceutical company with four clinical programs in development and a strong emerging pipeline, today reported financial results for the third quarter of 2022 and provided an update on recent corporate highlights.

Recent Corporate Highlights

  • On August 15, 2022, Inhibrx announced that the European Commission, based on a positive opinion issued by the European Medicines Agency, has granted orphan medicinal product designation to INBRX-109 for the treatment of chondrosarcoma.
    • Article Source
    Quick Links
    Categories
    Our Offices
    • 10kInfo, Inc.
      13555 SE 36th St
      Bellevue, WA 98006
    • 10kInfo Data Solutions, Pvt Ltd.
      Claywork Create
      11 km, Arakere Bannerghatta Rd, Omkar Nagar, Arekere,
      Bengaluru, Karnataka 560076
    4.2 12182024